跳至主要内容
临床试验/NCT06140875
NCT06140875招募中不适用

Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined with Radiochemotherapy and Maintenance Chemotherapy in Patients with Glioblastoma (Brain-RF)

Charite University, Berlin, Germany2 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2023年11月15日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
26
试验地点
2
主要终点
PFS at 6 months

研究概览

简要总结

Combined chemoradiation and radiofrequency electromagnetic field treatment for patients with glioblastoma

详细描述

Charité Universitätsmedizin Berlin is currently the only German University Hospital with an available capacitive radiofrequency electromagnetic field treatment device. While there is retrospective data available regarding the assumed effectiveness and low toxicity profile of radiofrequency electromagnetic field treatment for glioblastoma in the palliative setting, there is only few prospective data available on the combined effect first-line chemoradiation and radiofrequency electromagnetic field treatment. The investigators aim to conduct a feasibility trial and plan to compare the results with data of a prospective trial with a comparable patient population.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Pathological evidence of newly diagnosed glioblastoma according to WHO classification criteria
  • Patients 18 to 70 years of age with a WHO performance status of 2 or less
  • All patients must sign written informed consent
  • Adequate hematologic, renal, and hepatic function (absolute neutrophil count, ≥1,5 x 103/μL; platelet count, ≥100 x 103/μL; serum creatinine ≤1.7 mg/dL; total bilirubin > upper limit of normal; AST or ALT ≤3 times the upper limit of normal)
  • Patient must have received subtotal or gross total resection of the tumor
  • MGMT-promotor methylated patients must have refused therapy according to the CeTeG/NOA-09 protocol (+ Lomustin)
  • Patient must be planned for concomitant RCT with a total RT dose of 60 Gy over six weeks and temozolomide followed by six cycles of maintenance CT using temozolomide

排除标准

  • Previous cranial RT
  • Cytostatic therapy / anti-angiogenic substances / CT or radiation therapy for cancer within the past 5 years
  • History of cancers or other comorbidities that limit life expectancy to less than five years
  • Postoperative evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness)
  • Technical impossibility to use magnetic resonance imaging (MRI) or known allergies against MRI and/or computed tomography (CT) contrast agents
  • Technical impossibility to use AM-RF-EMF (pacemaker, defibrillator or deep brain stimulator, metal implants)
  • Participants of childbearing age unwilling to use or not capable of using effective contraception
  • Pregnant patients

结局指标

主要结局

PFS at 6 months

时间窗: 6 months after surgery or biopsy

Progression-free survival

次要结局

  • OS(Through study completion, an average of 15 months)
  • Acute and late toxicity(During 5,5 years of trial conduction)
  • Subsequent salvage treatment of the brain(During 5,5 years of trial conduction)
  • PFS(During 5,5 years of trial conduction)
  • Mini mental state examination(During 5,5 years of trial conduction)
  • Depression and anxiety testing(During 5,5 years of trial conduction)
  • QOL(During 5,5 years of trial conduction)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Pirus Ghadjar

Prof. Dr.

Charite University, Berlin, Germany

研究点 (2)

Loading locations...

相似试验